Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

New mutations in hair keratin genes cause the rare hair disorder monilethrix.

This study found that patients with alopecia areata face challenges like medical uncertainty and lack of information, highlighting the need for reliable and accessible treatment information that aligns with their preferences.

The Brigham Eyebrow Tool for Alopecia is a simple and reliable way to measure eyebrow hair loss.

This study found that patients with severe alopecia areata who experienced meaningful scalp hair regrowth showed greater improvements in health-related quality of life and reduced anxiety and depression compared to those with no or minimal regrowth.

This study found that middle-aged patients, patients in certain geographical regions, and female patients of specific age groups with alopecia areata face higher medical costs, indicating significant financial variability for affected subgroups.

This study evaluated the agreement between clinician and patient assessments of eyebrow and eyelash hair loss severity in adults with severe alopecia areata, using data from two phase 3 studies over 52 weeks.

People with alopecia who are more resilient tend to feel less stressed.

In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.

In this study, adults with significant alopecia areata were surveyed on their preferences for JAK inhibitor treatments, revealing a strong priority for scalp hair regrowth effectiveness and quicker initial regrowth over dosing convenience.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

This study found that nearly 40% of patients with severe alopecia areata who showed eyebrow or eyelash regrowth on baricitinib 4 mg achieved significant scalp hair regrowth by the second year of treatment.

This study found that using at least one ICD-10 code for alopecia in Medicaid claims data accurately identified alopecia in women of childbearing age, with positive predictive values between 95.3% and 100% across various algorithms tested.

In this study, adults with severe alopecia areata experienced greater improvements in hair regrowth, health-related quality of life, and reduced anxiety and depression symptoms after 36 weeks of treatment with baricitinib compared to placebo.

This study found that users of a German direct-to-consumer teledermatology platform for finasteride reported improvements in hair appearance and self-esteem, though 12% experienced treatment-related adverse events.

This review highlights the urgent need for increased research and policy support for autoimmune and immune-mediated skin diseases, which are on the rise and disproportionately affect women's health in the United States, suggesting a focus on gender and socioenvironmental factors.

This study found that the increasing visits to online prescription platforms for MQ-based finasteride treatment in androgenetic alopecia suggest a significant shift in medical care towards digital health services.

This study compared the effectiveness and safety of microneedling with PRP versus minoxidil and finasteride topical therapy in adult males with androgenetic alopecia, finding similar hair density improvements in both groups, though microneedling with PRP had a quicker onset of action.

Minoxidil helps hair regrowth in alopecia areata safely.

Minoxidil can help grow hair and make hair follicles bigger, but it can also cause side effects.

Minoxidil doesn't affect perifollicular lymphoid infiltration in alopecia areata patients.

This study found that androgenic alopecia is the strongest predictor of coronary artery disease in young men from Western India, followed by premature graying and obesity.

This perspective highlights evidence suggesting inflammation plays a significant role in male and female pattern hair loss, indicating that targeting inflammatory pathways may improve future therapeutic options.

This perspective highlights the role of inflammation in male and female pattern hair loss and its implications for developing future therapeutic options.

This study observed a high prevalence of PCOS among young female-pattern hair loss patients and suggested that AMH levels might be more indicative of FPHL than traditional androgens.

This exploratory pilot study found that topical sildenafil and minoxidil both significantly increased hair counts in male patients with androgenic alopecia, with varying effects at different scalp regions.

This review highlights bicalutamide as a promising oral therapy for female pattern hair loss, noting its safety, tolerability, and effectiveness in women with hyperandrogenic symptoms like acne and hirsutism, though further trials are needed to confirm its ideal dose and efficacy.

The authors provide an overview of using topical minoxidil to manage female pattern hair loss in Indian clinical practice, emphasizing its significance as the main treatment method.

This study found that 448-kHz Capacitive-Resistive Electrothermal Therapy led to a significant increase in hair density in women with Female Pattern Hair Loss, likely due to stimulated proliferation of dermal papilla cells.

This study evaluated donor area scars in hair restoration using a new assessment scale and found that most patients had good quality scars, with average scores of 15 or less out of 40.

A 73-year-old woman's unusual hair loss and growth led to the discovery of a rare condition causing too much testosterone, which improved after her ovaries were removed.